Several companies within Sahlgrenska Science Park have recently reached significant milestones, including a strategic acquisition and substantial capital secured to advance late-stage clinical trials in Europe and the United States. Together, these developments demonstrate growing clinical maturity, commercial validation, and increasing international investor confidence across the park’s portfolio.
“We are seeing clear evidence that companies from our portfolio are entering decisive growth phases, attracting strategic buyers, securing long-term capital, and preparing for international expansion,” says Cecilia Edebo, CEO of Sahlgrenska Science Park.
In recent weeks, a former incubator company, Sightic, announced its acquisition in a transaction valued at over SEK 60 million with a potential additional consideration of up to SEK 50 million, while portfolio company Verigraft AB secured SEK 110 million from a long-term shareholder to support preparations for Phase II/III clinical trials in Europe and the United States. At the end of last year, Verigraft was also awarded the Arvid Carlsson Award in recognition of its scientific excellence.
Together, these milestones illustrate the breadth of development within the ecosystem - from incubator-supported startups reaching successful exits to research-intensive companies advancing toward pivotal clinical programs in major international markets.
“We support science-based startups throughout their development journey, from early verification and business model development to capital raising, partnerships, and global expansion,” says Cecilia Edebo.
The recent progress reflects long-term collaboration between entrepreneurs, academia, healthcare, investors, and industry in Western Sweden.